LivaNova PLC $LIVN Shares Acquired by F m Investments LLC

F m Investments LLC boosted its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 46.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 114,458 shares of the company’s stock after purchasing an additional 36,543 shares during the quarter. F m Investments LLC’s holdings in LivaNova were worth $7,043,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in LivaNova by 4.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company’s stock valued at $1,394,000 after acquiring an additional 1,360 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in LivaNova by 4.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company’s stock valued at $32,012,000 after acquiring an additional 36,094 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in LivaNova by 10.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company’s stock valued at $6,633,000 after acquiring an additional 15,405 shares in the last quarter. Intech Investment Management LLC raised its stake in LivaNova by 19.6% during the 1st quarter. Intech Investment Management LLC now owns 43,879 shares of the company’s stock valued at $1,724,000 after acquiring an additional 7,195 shares in the last quarter. Finally, Strs Ohio bought a new stake in LivaNova during the 1st quarter valued at $130,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Ratings Changes

LIVN has been the topic of several recent analyst reports. Mizuho lifted their target price on LivaNova from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Thursday. Robert W. Baird cut their target price on LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research note on Thursday. Needham & Company LLC lifted their target price on LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $66.00 target price on shares of LivaNova in a research note on Friday, January 9th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $85.00 target price on shares of LivaNova in a research note on Thursday, February 19th. Seven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, LivaNova currently has a consensus rating of “Moderate Buy” and an average price target of $77.22.

LivaNova Stock Up 1.3%

NASDAQ:LIVN opened at $71.86 on Friday. The firm has a market capitalization of $3.95 billion, a price-to-earnings ratio of 36.85 and a beta of 0.82. LivaNova PLC has a 1-year low of $41.01 and a 1-year high of $72.51. The company has a current ratio of 1.33, a quick ratio of 1.16 and a debt-to-equity ratio of 0.24. The business’s fifty day moving average price is $64.01 and its 200 day moving average price is $62.15.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.13. The firm had revenue of $362.26 million for the quarter, compared to analyst estimates of $346.05 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.LivaNova’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.88 earnings per share. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, sell-side analysts forecast that LivaNova PLC will post 3.66 earnings per share for the current fiscal year.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.